MedTrace Logo

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

NCT06715683 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-04-04

No results posted yet for this study

Summary

This is a trial to evaluate the comparative bioavailability of BMS-986278 to-be-marketed formulation compared to the phase 3 clinical trial formulation in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

BMS-986278 Batched method, Dose A

Specified dose on specified days

DRUG

BMS-986278 Batched method, Dose B

Specified dose on specified days

DRUG

BMS-986278 Continuous method

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-12
Primary Completion
2025-03-16
Completion
2025-03-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06715683 on ClinicalTrials.gov